Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
A differentiated T-cell repertoire (CD8+CD45RA+CD62L-CCR7- T effector cells re-expressing CD45RA (TEMRA)) may define a functionally high-risk group (median time to progression of 2.1 years) of smoldering myeloma patients.”
Title: A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients
Authors: Ross S. Firestone, Anish K. Simhal, Theresia Akhlaghi, Jung Hun Oh, Devin McAvoy, Kylee H. Maclachlan, Juan-Jose Garces, Sham Mailankody, Hani Hassoun, Urvi A. Shah, Neha Korde, Carlyn R. Tan, Sridevi Rajeeve, Hamza Hashmi, Alexander M. Lesokhin, Kinga Hosszu, Francesco Maura, Joseph O. Deasy, Saad Z. Usmani, Malin Hultcrantz
You can read the Full Article in Blood Cancer Journal.
You can find other articles featuring Robert Orlowski on OncoDaily.
